Trial Profile
FASENRA Subcutaneous Injection 30 mg Syringe Specific Clinical Experience Investigation for Long-term Use
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors AstraZeneca
- 05 Oct 2020 Status changed from recruiting to active, no longer recruiting.
- 20 Jul 2018 New trial record